The Shizuoka-based company operates five factories, which are focused on contract manufacturing and packaging services of soft capsules, seamless capsules and other dosage forms for H&N and pharmaceutical use.
Carlyle will make the investment from its Japan Partners III fund, which is targeting JPY100bn ($980m), which is below the JPY165.6bn raised by its second Japanese vehicle in 2006.
In January this year it was reported that Carlyle had secured JPY45bn ($436m) for the fund.
Carlyle managing director Takaomi Tomioka said, “Sunsho Pharmaceutical has established a solid position as a contract manufacturer in the steadily growing H&N market in Japan.
“With its competitive edge in R&D and manufacturing capabilities, the company is poised for continued growth.
“We were impressed by Sunsho Pharmaceutical’s competitive positioning and growth potential, and have a strong appreciation of its management philosophy and culture.”
Meanwhile, Carlyle is reportedly in talks to buy Japanese snack maker Oyatsu for more than $250m.
Copyright © 2014 AltAssets